Propyl Gallate vs Carrageenan: which is worse?

What is Propyl Gallate?

Propyl gallate is a synthetic antioxidant preservative derived from gallic acid and propanol. It prevents oxidation of fats and oils, extending shelf life of fat-containing foods. It is often used in combination with BHA and BHT for synergistic antioxidant effect. Chemical formula: C10H12O5.

What is Carrageenan?

Carrageenan is a polysaccharide extracted from red seaweed (primarily Chondrus crispus and Eucheuma species). Used as a thickener, gelling agent, and stabilizer in food and personal care products. Food-grade carrageenan (undegraded) is different from degraded carrageenan (poligeenan), which is not food-grade and is a known inflammatory agent.

Documented risks

Propyl Gallate: Animal studies have shown propyl gallate may cause liver damage at high doses. Concerns about estrogenic activity have been raised — some studies suggest propyl gallate may weakly mimic estrogen. Contact dermatitis and allergic reactions are documented in both food and cosmetic applications. Japan banned propyl gallate for food use as part of its precautionary approach to synthetic food preservatives. NTP bioassays found dose-dependent liver effects. EFSA's re-evaluation set an ADI of 0.1 mg/kg body weight — one of the lowest ADIs for food additives, reflecting toxicological concern.

Carrageenan: Carrageenan safety has been disputed for decades, centering on the distinction between undegraded (food-grade, high-molecular-weight) carrageenan and degraded carrageenan (poligeenan). Poligeenan, produced by acid hydrolysis, is a known inflammatory and carcinogenic agent in animals. Food-grade carrageenan is a different molecule, but critics argue it can partially degrade in the acidic stomach environment. Dr. Joanne Tobacman at the University of Illinois has published multiple studies on carrageenan-induced inflammation. A 2001 paper in Environmental Health Perspectives (PMC1240867) demonstrated that food-grade carrageenan activates inflammatory signaling pathways (NF-κB) in human intestinal cells, inhibits insulin signaling, and causes intestinal injury in animal models. Her 2012 review in the Journal of Diabetes Research summarized multiple animal studies showing intestinal inflammation, ulcerations, and neoplasms. A 2017 review in Environmental Health Perspectives (Bhide et al.) found carrageenan activated NF-κB inflammatory pathways and could potentially exacerbate inflammatory bowel disease (IBD) in susceptible individuals. Major regulatory bodies including EFSA (comprehensive 2018 re-evaluation) and the WHO/FAO JECFA have consistently concluded that undegraded food-grade carrageenan does not cause cancer or significant harm at typical food use levels in healthy adults. However, the EU precautionary ban in infant formula (2018) acknowledged that infants' developing digestive systems may be more vulnerable to carrageenan's potential effects, and insufficient evidence of safety existed for this specific high-risk population. The USDA's removal of carrageenan from Organic certification (2018) reflected organic industry stakeholder concern despite the continued regulatory permission. Individuals with IBD or gut sensitivity may have reason to avoid carrageenan based on in vitro and animal data, even if the general population safety at food use levels is defended by EFSA and JECFA.